Categories Earnings, Health Care

Amicus Therapeutics (FOLD): Q3 2019 Earnings Snapshot

Earnings Update by AlphaStreet

— Amicus Therapeutics (NASDAQ: FOLD) reported Q3 2019 loss of $0.24 per share, vs. a loss of $0.32 expected.

— Revenues grew 137% to $48.8 million, vs. $47.6 million expected.

— Global revenue for Galafold was $48.8 million.

— FY19 Galafold revenue is expected to be $170 million to $180 million.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

PepsiCo (PEP) expects snacks business to remain resilient in the near term

PepsiCo Inc. (NASDAQ: PEP) reported first quarter 2021 earnings results on Thursday that topped expectations on both the top and bottom lines. The stock has gained 7% in the past

For Wells Fargo (WFC), Q1 sets the stage for long-term recovery

Emerging from the slowdown caused by coronavirus, the financial services sector entered fiscal 2021 on a bright note, thanks to improving economic activity and the COVID-driven boom in stock trading.

Top 3 Artificial Intelligence stocks you may consider in 2021

Artificial Intelligence has become an integral part of the US economy. According to the analyst’s insights, AI market revenue in 2020 was $25.9 billion. The AI market in the North

Add Comment
Viewing Highlight